FDA发布ANDA审评优先级MaPP修订稿
首页 > 资讯 > FDA发布ANDA审评优先级MaPP修订稿 出自识林
FDA发布ANDA审评优先级MaPP修订稿
笔记 2016-03-12 Lachman CONSULTANTS 3月11日FDA发布《MaPP5240.3 原始ANDA、增补和补充审评的优先级》修订稿。MaPP(政策和流程手册)是FDA的内部政策和程序,指导FDA内部工作。这篇MaPP的主要内容是简单易懂的,但有几个问题可能需要进一步澄清。 新修订的MaPP概述了加速审评过程的历史,但没有回溯到非常早的仿制药办公室(OGD)政策和程序指导(38-93及其前身16-90和21-90)。这显然被认为是OGD的古老历史(尽管许多相同的规定适用)。OGD接着解释了一些监管和法律规定,以及在审评过程中的变化和2012年仿制药使用者付费法案对政策的影响。 应认真审查和研究整个MaPP,从而能最好的明白FDA关于优先和加速审评的立场。我想指出一些重要问题:
这篇MaPP对回答企业可以对GDUFA下的优先和加速申请期待些什么大有帮助。这也是GDUFA II谈判正在讨论的要点之一,这MaPP肯定会成为企业评议的起点。 *“如果参照药品提交的专利是使用方法专利,并且不是ANDA寻求批准的使用方法的权利要求”,ANDA申请人可以“声明使用方法专利的权利要求没有这个使用方法”(也称为“小八条”)(FD&C Act 第505(j)(2)(A)(viii)节,同样也参考 21 CFR 314.94(a)(12)(iv))。 Lachman CONSULTANTS - Bob Pollock先生 MaPP 5240.3 on Prioritization of Original ANDAs, Amendments, and Supplements Gets a Facelift By Bob Pollock | March 11, 2016 Life is always a picnic and deciding what to bring is sometimes a chore. The key is to assure there are no ants! Well, the generic industry has waited to hear what would be brought to the prioritization picnic and now the third revision of the MaPP 5240.3 lays out the meal. But with every complex meal there are some foods you don’t find appealing. In the case of this MaPP (remember, a MaPP is an internal FDA document that instructs the FDA how they are to do business), things seem largely straightforward, but there are a few issues that may need further clarification. The new MaPP outlines the history of the expedited review process, but does not go back to the very early days of OGD’s Policy and Procedure Guides (38-93 and its predecessors 16-90 and 21-90). That clearly is considered ancient history by OGD (albeit many of the same provisions apply). OGD goes on to explain some of the regulatory and statutory provisions, as well as changes in the review process and the impact of the Generic Drug User Fee Act of 2012 on the policy. The entire MaPP (here) should be reviewed and studied carefully so you best understand the FDA position on priority and expedited review. I would, however, would like to point out some important issues.
“ANDAs submitted more than 30 months in advance of the last applicable patent expiration date or exclusivity date will not be considered for expedited review.” Here I have a problem. If FDA is pressed to meet the 30-month review for Tentative Approval or Approval, wouldn’t they want some additional window (like an additional 6 months or 36 months) to further assure they can meet the date? I guess they are fully confident that they can meet the 30-month clock!
The MaPP goes a long way to answering what industry can expect for priority and expedited review under GDUFA. This is also one of the points being discussed for the GDUFA II negotiations and will certainly be a starting point for industry comments. |